O Shaughnessy Asset Management LLC Purchases 19,305 Shares of Thermo Fisher Scientific Inc. $TMO

O Shaughnessy Asset Management LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 43.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 63,671 shares of the medical research company’s stock after acquiring an additional 19,305 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $36,894,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Manchester Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 5.3% in the 4th quarter. Manchester Capital Management LLC now owns 2,012 shares of the medical research company’s stock worth $1,166,000 after acquiring an additional 101 shares during the last quarter. Napier Financial LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $4,202,000. RWC Asset Management LLP lifted its holdings in Thermo Fisher Scientific by 47.0% during the 4th quarter. RWC Asset Management LLP now owns 701 shares of the medical research company’s stock valued at $406,000 after buying an additional 224 shares in the last quarter. CNB Bank lifted its holdings in Thermo Fisher Scientific by 3.3% during the 4th quarter. CNB Bank now owns 2,405 shares of the medical research company’s stock valued at $1,394,000 after buying an additional 76 shares in the last quarter. Finally, Syon Capital LLC lifted its holdings in Thermo Fisher Scientific by 6.4% during the 4th quarter. Syon Capital LLC now owns 3,822 shares of the medical research company’s stock valued at $2,215,000 after buying an additional 231 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.0%

NYSE TMO opened at $472.98 on Monday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The company has a market capitalization of $175.77 billion, a price-to-earnings ratio of 26.00, a price-to-earnings-growth ratio of 2.09 and a beta of 0.88. The company’s 50-day simple moving average is $479.94 and its two-hundred day simple moving average is $530.83. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TMO has been the subject of a number of research analyst reports. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price objective for the company from $670.00 to $540.00 in a report on Wednesday. DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They set a “buy” rating and a $610.00 price objective for the company. Morgan Stanley reiterated an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $613.67.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.